

Mark J Mckeage

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5903262/publications.pdf>

Version: 2024-02-01

98
papers

4,690
citations

109321

35
h-index

102487

66
g-index

99
all docs

99
docs citations

99
times ranked

5538
citing authors

#	ARTICLE	IF	CITATIONS
1	Randomized Phase III Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the Vascular Disrupting Agent Vadimezan (ASA404) in Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 2965-2971.	1.6	282
2	Comparative Adverse Effect Profiles of Platinum Drugs. <i>Drug Safety</i> , 1995, 13, 228-244.	3.2	271
3	Mechanisms of cytotoxicity and antitumor activity of gold(I) phosphine complexes: the possible role of mitochondria. <i>Coordination Chemistry Reviews</i> , 2002, 232, 127-135.	18.8	230
4	Role of lipophilicity in determining cellular uptake and antitumour activity of gold phosphine complexes. <i>Cancer Chemotherapy and Pharmacology</i> , 2000, 46, 343-350.	2.3	197
5	In vitro antitumour and hepatotoxicity profiles of Au(I) and Ag(I) bidentate pyridyl phosphine complexes and relationships to cellular uptake. <i>Journal of Inorganic Biochemistry</i> , 2008, 102, 303-310.	3.5	174
6	ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non-Small Cell Lung Cancer (NSCLC). <i>Journal of Thoracic Oncology</i> , 2017, 12, 1357-1367.	1.1	144
7	Platinum neurotoxicity: clinical profiles, experimental models and neuroprotective approaches. <i>Journal of Inorganic Biochemistry</i> , 1999, 77, 105-110.	3.5	138
8	Lobaplatin: a new antitumour platinum drug. <i>Expert Opinion on Investigational Drugs</i> , 2001, 10, 119-128.	4.1	138
9	Disrupting established tumor blood vessels. <i>Cancer</i> , 2010, 116, 1859-1871.	4.1	138
10	Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. <i>British Journal of Cancer</i> , 2008, 99, 2006-2012.	6.4	129
11	Structural and solution chemistry of gold(I) and silver(I) complexes of bidentate pyridyl phosphines: selective antitumour agents. <i>Coordination Chemistry Reviews</i> , 1999, 185-186, 823-836.	18.8	115
12	Oxaliplatin Transport Mediated by Organic Cation/Carnitine Transporters OCTN1 and OCTN2 in Overexpressing Human Embryonic Kidney 293 Cells and Rat Dorsal Root Ganglion Neurons. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2011, 338, 537-547.	2.5	112
13	Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed. <i>Journal of Structural Biology</i> , 2015, 192, 539-544.	2.8	106
14	Oxaliplatin causes selective atrophy of a subpopulation of dorsal root ganglion neurons without inducing cell loss. <i>Cancer Chemotherapy and Pharmacology</i> , 2005, 56, 391-399.	2.3	105
15	Nucleolar damage correlates with neurotoxicity induced by different platinum drugs. <i>British Journal of Cancer</i> , 2001, 85, 1219-1225.	6.4	100
16	Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). <i>Cancer Chemotherapy and Pharmacology</i> , 2003, 51, 43-52.	2.3	95
17	A phase I and pharmacology study of an oral platinum complex, JM216: dose-dependent pharmacokinetics with single-dose administration. <i>Cancer Chemotherapy and Pharmacology</i> , 1995, 36, 451-458.	2.3	93
18	Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m ² combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2009, 65, 192-197.	2.0	92

#	ARTICLE	IF	CITATIONS
19	5,6-Dimethylxanthenone-4-Acetic Acid in the Treatment of Refractory Tumors: a Phase I Safety Study of a Vascular Disrupting Agent. <i>Clinical Cancer Research</i> , 2006, 12, 1776-1784.	7.0	90
20	Rapid biotransformation of satraplatin by human red blood cells in vitro. <i>Cancer Chemotherapy and Pharmacology</i> , 2002, 50, 9-15.	2.3	87
21	Satraplatin activation by haemoglobin, cytochrome C and liver microsomes in vitro. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 57, 483-490.	2.3	83
22	A Phase I Study of AS1409, a Novel Antibody-Cytokine Fusion Protein, in Patients with Malignant Melanoma or Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2011, 17, 1998-2005.	7.0	82
23	Preparation, DNA Binding, and in Vitro Cytotoxicity of a Pair of Enantiomeric Platinum(II) Complexes, [(R)- and (S)-3-Amino-6-hydroxy-2-phenylpyridine]dichloro-platinum(II). Crystal Structure of the S-Enantiomer. <i>Journal of Medicinal Chemistry</i> , 1997, 40, 1090-1098.	6.4	65
24	Antitumor Activity of Gold(I), Silver(I) and Copper(I) Complexes Containing Chiral Tertiary Phosphines. <i>Metal-Based Drugs</i> , 1998, 5, 217-223.	3.8	65
25	Phase IB Trial of the Anti-Cancer Stem Cell DLL4-Binding Agent Demcizumab with Pemetrexed and Carboplatin as First-Line Treatment of Metastatic Non-Squamous NSCLC. <i>Targeted Oncology</i> , 2018, 13, 89-98.	3.6	63
26	Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)-Positive NSCLC: Primary Efficacy Results From the ASCEND-8 Study. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1255-1265.	1.1	59
27	A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients. <i>BMC Cancer</i> , 2011, 11, 432.	2.6	56
28	Membrane Transporters as Determinants of the Pharmacology of Platinum Anticancer Drugs. <i>Current Cancer Drug Targets</i> , 2012, 12, 962-986.	1.6	55
29	cis-Dichloroplatinum(II) complexes tethered to 9-aminoacridine-4-carboxamides: synthesis and action in resistant cell lines in vitro. <i>Journal of Inorganic Biochemistry</i> , 2001, 85, 209-217.	3.5	50
30	Neuronal expression of copper transporter 1 in rat dorsal root ganglia: association with platinum neurotoxicity. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 64, 847-856.	2.3	49
31	PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours. <i>BMC Cancer</i> , 2012, 12, 496.	2.6	49
32	New-generation platinum drugs in the treatment of cisplatin-resistant cancers. <i>Expert Opinion on Investigational Drugs</i> , 2005, 14, 1033-1046.	4.1	42
33	Detecting acute neurotoxicity during platinum chemotherapy by neurophysiological assessment of motor nerve hyperexcitability. <i>BMC Cancer</i> , 2010, 10, 451.	2.6	42
34	Specific determination of intact cisplatin and monohydrated cisplatin in human plasma and culture medium ultrafiltrates using HPLC on-line with inductively coupled plasma mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2006, 837, 29-34.	2.3	39
35	Lack of nephrotoxicity of oral ammine/amine platinum (IV) dicarboxylate complexes in rodents. <i>British Journal of Cancer</i> , 1993, 67, 996-1000.	6.4	38
36	Preparation, Characterization, DNA Binding, and in Vitro Cytotoxicity of the Enantiomers of the Platinum(II) Complexes N-Methyl-, N-Ethyl- and N,N-Dimethyl-(R)- and -(S)-3-amino-6-hydroxy-2-phenylpyridine-dichloroplatinum(II). <i>Journal of Medicinal Chemistry</i> , 1997, 40, 3508-3515.	6.4	34

#	ARTICLE	IF	CITATIONS
37	Contributions of rat Ctr1 to the uptake and toxicity of copper and platinum anticancer drugs in dorsal root ganglion neurons. <i>Biochemical Pharmacology</i> , 2013, 85, 207-215.	4.4	34
38	The potential of DMXAA (ASA404) in combination with docetaxel in advanced prostate cancer. <i>Expert Opinion on Investigational Drugs</i> , 2008, 17, 23-29.	4.1	32
39	Multidrug Resistance-Associated Protein 2 (MRP2) Mediated Transport of Oxaliplatin-Derived Platinum in Membrane Vesicles. <i>PLoS ONE</i> , 2015, 10, e0130727.	2.5	32
40	Plasma pharmacokinetics of the antitumour agents 5,6-dimethylxanthenone-4-acetic acid, xanthenone-4-acetic acid and flavone-8-acetic acid in mice. <i>Cancer Chemotherapy and Pharmacology</i> , 1991, 28, 409-413.	2.3	31
41	Quantitative determination of platinum complexes in human plasma generated from the oral antitumour drug JM216 using directly coupled high-performance liquid chromatography-inductively coupled plasma mass spectrometry without desolvation. <i>Journal of Analytical Atomic Spectrometry</i> , 1999, 14, 953-956.	3.0	31
42	Role of platinum DNA damage-induced transcriptional inhibition in chemotherapy-induced neuronal atrophy and peripheral neurotoxicity. <i>Journal of Neurochemistry</i> , 2015, 135, 1099-1112.	3.9	31
43	Differential Expression of ATP7A, ATP7B and CTR1 in Adult Rat Dorsal Root Ganglion Tissue. <i>Molecular Pain</i> , 2010, 6, 1744-8069-6-53.	2.1	30
44	Comparative outcomes of squamous and non-squamous non-small cell lung cancer (NSCLC) patients in phase II studies of ASA404 (DMXAA) - retrospective analysis of pooled data. <i>Journal of Thoracic Disease</i> , 2010, 2, 199-204.	1.4	30
45	Nucleolar enlargement, nuclear eccentricity and altered cell body immunostaining characteristics of large-sized sensory neurons following treatment of rats with paclitaxel. <i>NeuroToxicology</i> , 2007, 28, 1092-1098.	3.0	29
46	Oxaliplatin-Induced Loss of Phosphorylated Heavy Neurofilament Subunit Neuronal Immunoreactivity in Rat Drg Tissue. <i>Molecular Pain</i> , 2009, 5, 1744-8069-5-66.	2.1	27
47	Final Overall Survival and Other Efficacy and Safety Results From ASCEND-3: Phase II Study of Ceritinib in ALK-Positive Patients With ALK-Rearranged NSCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 609-617.	1.1	27
48	Gold opens mitochondrial pathways to apoptosis. <i>British Journal of Pharmacology</i> , 2002, 136, 1081-1082.	5.4	24
49	Paclitaxel induces nucleolar enlargement in dorsal root ganglion neurons in vivo reducing oxaliplatin toxicity. <i>British Journal of Cancer</i> , 2003, 88, 1942-1947.	6.4	23
50	Hormone Resistance in Two MCF-7 Breast Cancer Cell Lines is Associated with Reduced mTOR Signaling, Decreased Glycolysis, and Increased Sensitivity to Cytotoxic Drugs. <i>Frontiers in Oncology</i> , 2014, 4, 221.	2.8	23
51	Platinum-specific detection and quantification of oxaliplatin and Pt(R,R-diaminocyclohexane)Cl ₂ in the blood plasma of colorectal cancer patients. <i>Journal of Analytical Atomic Spectrometry</i> , 2008, 23, 881.	3.0	22
52	Increased targeting of adenine-rich sequences by (2-amino-2-methyl-3-butanone) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 147 Td (oxime) d Inorganic Chemistry, 2000, 5, 675-681.	2.6	20
53	Antitumour action of 5,6-dimethylxanthenone-4-acetic acid in rats bearing chemically induced primary mammary tumours. <i>Cancer Chemotherapy and Pharmacology</i> , 2007, 59, 661-669.	2.3	20
54	COMPARATIVE PROTEIN BINDING, STABILITY AND DEGRADATION OF SATRAPLATIN, JM118 AND CISPLATIN IN HUMAN PLASMA <i>IN VITRO</i>. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2008, 35, 1440-1446.	1.9	20

#	ARTICLE	IF	CITATIONS
55	Phase I drug-interaction study of effects of calcium and magnesium infusions on oxaliplatin pharmacokinetics and acute neurotoxicity in colorectal cancer patients. <i>BMC Cancer</i> , 2013, 13, 495.	2.6	20
56	Preclinical toxicology and tissue platinum distribution of novel oral antitumour platinum complexes: ammine/amine platinum(IV) dicarboxylates. <i>Cancer Chemotherapy and Pharmacology</i> , 1994, 33, 497-503.	2.3	19
57	Mechanism of action of an orally administered platinum complex [ammine bis butyrato cyclohexylamine dichloroplatinum (IV) (JM221)] in intrinsically cisplatin-resistant human ovarian carcinoma in vitro. <i>British Journal of Cancer</i> , 1994, 69, 1-7.	6.4	19
58	The Effects of Synthetically Modified Natural Compounds on ABC Transporters. <i>Pharmaceutics</i> , 2018, 10, 127.	4.5	19
59	ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients with <i>ALK</i> -Positive Non-Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges. <i>Clinical Cancer Research</i> , 2022, 28, 2506-2516.	7.0	19
60	5,6-Dimethylxanthenone-4-Acetic Acid (DMXAA). <i>American Journal of Cancer</i> , 2006, 5, 155-162.	0.4	18
61	Identification of MRP2 as a targetable factor limiting oxaliplatin accumulation and response in gastrointestinal cancer. <i>Scientific Reports</i> , 2019, 9, 2245.	3.3	18
62	Non-surgical aspects of ovarian cancer. <i>Lancet</i> , The, 1994, 343, 335-340.	13.7	17
63	Preventing oxaliplatin-induced neurotoxicity: rationale and design of phase Ib randomized, double-blind, placebo-controlled, cross-over trials for early clinical evaluation of investigational therapeutics. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 1479-1490.	3.3	17
64	Copper transporter 1 in human colorectal cancer cell lines: Effects of endogenous and modified expression on oxaliplatin cytotoxicity. <i>Journal of Inorganic Biochemistry</i> , 2017, 177, 249-258.	3.5	17
65	Transport-Mediated Oxaliplatin Resistance Associated with Endogenous Overexpression of MRP2 in Caco-2 and PANC-1 Cells. <i>Cancers</i> , 2019, 11, 1330.	3.7	17
66	New Platinum Agents. <i>Drugs and Aging</i> , 1994, 5, 85-95.	2.7	16
67	ASA404: a tumor vascular-disrupting agent with broad potential for cancer therapy. <i>Future Oncology</i> , 2010, 6, 1537-1543.	2.4	16
68	Satraplatin in Hormone-Refractory Prostate Cancer and Other Tumour Types. <i>Drugs</i> , 2007, 67, 859-869.	10.9	15
69	Application of liquid chromatography-mass spectrometry to monitoring plasma cyclophosphamide levels in phase I trial cancer patients*. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2004, 31, 677-682.	1.9	14
70	Transient Retinal Effects of 5,6-Dimethylxanthenone-4-acetic Acid (DMXAA, ASA404), an Antitumor Vascular-Disrupting Agent in Phase I Clinical Trials. , 2009, 50, 2553.		14
71	Utilisation and Determinants of Epidermal Growth Factor Receptor Mutation Testing in Patients with Non-small Cell Lung Cancer in Routine Clinical Practice: A Global Systematic Review. <i>Targeted Oncology</i> , 2020, 15, 279-299.	3.6	14
72	Emerging roles of metal solute carriers in cancer mechanisms and treatment. <i>Biopharmaceutics and Drug Disposition</i> , 2014, 35, 450-462.	1.9	13

#	ARTICLE	IF	CITATIONS
73	Examination of the effects of oxidation and ring closure on the cytotoxicities of the platinum complexes of N-(2-hydroxyethyl)ethane-1,2-diamine and ethane-1,2-diamine-N,Nâ€²-diacetic acid. <i>Journal of Inorganic Biochemistry</i> , 2002, 91, 205-211.	3.5	12
74	Clinical Trials of Vascular Disrupting Agents in Advanced Nonâ€“Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2011, 12, 143-147.	2.6	12
75	EGFR Mutation Testing of non-squamous NSCLC: Impact and Uptake during Implementation of Testing Guidelines in a Population-Based Registry Cohort from Northern New Zealand. <i>Targeted Oncology</i> , 2017, 12, 663-675.	3.6	12
76	Lung cancer mutation testing: a clinical retesting study of agreement between a real-time PCR and a mass spectrometry test. <i>Oncotarget</i> , 2017, 8, 101437-101451.	1.8	12
77	Anticancer potential of tumor vascular disrupting agents: review of the latest clinical evidence. <i>Clinical Investigation</i> , 2012, 2, 985-993.	0.0	11
78	Evaluation of effects of copper histidine on copper transporter 1â€“mediated accumulation of platinum and oxaliplatinâ€“induced neurotoxicity <i>in vitro</i> and <i>in vivo</i>. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2013, 40, 371-378.	1.9	10
79	Screening for anaplastic lymphoma kinase (<i>ALK</i>) gene rearrangements in nonâ€“smallâ€“cell lung cancer in New Zealand. <i>Internal Medicine Journal</i> , 2020, 50, 716-725.	0.8	9
80	Haematological effects in mice of the antitumour agents xanthenone-4-acetic acid, 5,6-methyl-xanthenone-4-acetic acid and flavone acetic acid. <i>Cancer Chemotherapy and Pharmacology</i> , 1991, 28, 414-419.	2.3	8
81	Tamoxifen and Chemotherapy for Refractory Metastatic Malignant Melanoma. <i>New England Journal of Medicine</i> , 1993, 328, 140-141.	27.0	8
82	Selective antitumour activity of metal complexes of bidentate pyridylphosphines. <i>Journal of Inorganic Biochemistry</i> , 1997, 67, 154.	3.5	8
83	Selective cellular uptake and retention of SN 28049, a new DNA-binding topoisomerase II-directed antitumor agent. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 25-35.	2.3	8
84	Predicting effects on oxaliplatin clearance: in vitro, kinetic and clinical studies of calcium- and magnesium-mediated oxaliplatin degradation. <i>Scientific Reports</i> , 2017, 7, 4073.	3.3	8
85	Incomplete uptake of EGFR mutation testing and its impact on estimation of mutation prevalence in patients with non-squamous NSCLC: A population-based study in New Zealand. <i>Cancer Epidemiology</i> , 2018, 57, 24-32.	1.9	8
86	Reply to E.S. Wang et al. <i>Journal of Clinical Oncology</i> , 2012, 30, 761-762.	1.6	7
87	New Platinum Drugs. , 1993, , 169-212.		7
88	Capecitabine and oral cyclophosphamide: A novel oral treatment combination for advanced cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2007, 3, 99-105.	1.1	6
89	Mass balance, excretion and metabolism of [14C] ASA404 in cancer patients in a phase I trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 1145-1154.	2.3	5
90	Neuropathies associated with oxaliplatin therapy. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2012, 8, 107-110.	1.1	4

#	ARTICLE	IF	CITATIONS
91	Muscle ultrasound in the assessment of oxaliplatin-induced neurotoxicity. <i>Clinical Neurophysiology</i> , 2020, 131, 343-344.	1.5	4
92	The Clinical Development of the Oral Platinum Anticancer Agent JM216. , 1996, , 83-89.		4
93	Vinblastine Pharmacokinetics in Patients with Non-Small Cell Lung Cancer Given Cisplatin. <i>Cancer Investigation</i> , 1999, 17, 479-485.	1.3	3
94	Osimertinib in NSCLC: Real-World Data From New Zealand. <i>JTO Clinical and Research Reports</i> , 2020, 1, 100022.	1.1	3
95	A clinical and pharmacological study of high-dose mitozolomide given in conjunction with autologous bone marrow rescue. <i>Cancer Chemotherapy and Pharmacology</i> , 1992, 29, 201-206.	2.3	2
96	Preclinical toxicology and tissue platinum distribution of novel oral antitumour platinum complexes: ammine/amine platinum(IV) dicarboxylates. <i>Cancer Chemotherapy and Pharmacology</i> , 1994, 33, 497-503.	2.3	2
97	Therapeutic targeting of tumor angiogenesis: how far have we come?. <i>Clinical Investigation</i> , 2014, 4, 1113-1122.	0.0	0
98	Tumour Mutation Profiling with High-throughput Multiplexed Genotyping: A Review of its Use for Guiding Targeted Cancer Therapy. <i>Current Cancer Therapy Reviews</i> , 2014, 9, 236-244.	0.3	0